Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: A prospective, randomized, doubled-masked comparison of safety and efficacy

Eye

Volumn 25, Issue 9, 2011, Pages 1161-1169

  Kitazawa, Y ^a   Smith, P ^b   Sasaki, N ^c   Kotake, S ^b   Bae, K ^b   Iwamoto, Y ^c  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ALCON RESEARCH LTD   (United States)

^c Alcon Japan   (Japan)

Author keywords

benzalkonium chloride; glaucoma; intraocular pressure; prostaglandin analogs; timolol; travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; TIMOLOL PLUS TRAVOPROST;

ADULT; AGED; BRADYCARDIA; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHOTOPHOBIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 80052623756     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.134     Document Type: Review

References (33)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80(5): 389-393. (Pubitemid 26158268)
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90(3): 262-267. (Pubitemid 43325451)
3. Tsai JH, Derby E, Holland EJ, Khatana AK. Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea 2006; 25(5): 530-532. (Pubitemid 44641588)
4. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17(5): 350-355.
5. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996; 7(2): 80-86. (Pubitemid 26268834)
6. Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology 1999; 106(3): 556-563. (Pubitemid 30191592)
7. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000; 20(2): 85-94. (Pubitemid 30099159)
8. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23(5): 490-496. (Pubitemid 38857008)
9. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23(5): 663-671. (Pubitemid 44955845)
10. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008; 27(3): 339-343. (Pubitemid 351440870)
11. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008; 25(8): 743-751.
12. Yamakazi S, Nanno M, Kimura T, Suzumura H, Yoshikawa K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol 2010; 54(1): 7-14.
13. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120(6): 701-713. (Pubitemid 34620348)
14. Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE et al. Travoprost 0.004% with and without benzalkonium chloride: A comparison of safety and efficacy. J Glaucoma 2007; 16(1): 98-103. (Pubitemid 46114782)
15. Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006; 113(8): 1333-1339. (Pubitemid 44108169)
16. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002; 11(2): 119-126. (Pubitemid 34298592)
17. Hutnik C, Neima D, Ibrahim F et al. Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2010; 4: 581-590.
18. Labbe A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet JM et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: An experimental study. J Ocul Pharmacol Ther 2006; 22(4): 267-278. (Pubitemid 44689667)
19. Schuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005; 140(2): 242-250.
20. Topouzis F, Melamed S, Danesh-Meyer H. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/ timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17: 183-190. (Pubitemid 46918103)
21. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126(4): 498-505.
22. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126(4): 487-497.
23. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130(4): 429-440.
24. Mundorf TK, Ogawa T, Naka H, Novack GD, Crockett RS, US Istalol Study Group. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther 2004; 26(4): 541-551. (Pubitemid 38586455)
25. Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of non-preserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J Fr Ophtalmol 2003; 26(7): 668-674. (Pubitemid 37173418)
26. Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 2008; 17(3): 217-222. (Pubitemid 351543547)
27. Miyake K, Ibaraki N, Goto Y, Oogiya S, Ishigaki J, Ota I et al. ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy. J Cataract Refract Surg 2003; 29(9): 1800-1810.
28. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112(11): 1446-1454. (Pubitemid 24350507)
29. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007; 48(9): 4123-4128. (Pubitemid 351261038)
30. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006; 23(4): 511-519.
31. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15(2): 132-135. (Pubitemid 38457133)
32. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007; 24(12): 1007-1016. (Pubitemid 350145409)
33. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: A systematic classification. J Glaucoma 2003; 12(5): 393-398. (Pubitemid 37237370)